Long-term findings from COMFORT-II, a phase 3 study of ruxolitinib vs best available therapy for myelofibrosis

Leukemia

Volumn 30, Issue 8, 2016, Pages 1701-1707

  Harrison, C N ^a   Vannucchi, A M ^b   Kiladjian, J J ^c   Al Ali, H K ^d   Gisslinger, H ^e   Knoops, L ^f   Cervantes, F ^g   Jones, M M ^h   Sun, K ^h   McQuitty, M ⁱ   Stalbovskaya, V ⁱ   Gopalakrishna, P ⁱ   Barbui, T ^j  

^a GUY S HOSPITAL   (United Kingdom)

^b UNIVERSITY OF FLORENCE   (Italy)

^c SAINT LOUIS HOSPITAL   (France)

^d UNIVERSITY OF LEIPZIG   (Germany)

^e MEDICAL UNIVERSITY OF VIENNA   (Austria)

^f CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^g HOSPITAL CLÍNIC   (Spain)

^h Drug Metabolism Pharmacokinetics Clinical Pharmacology   (United States)

ⁱ NOVARTIS PHARMA AG   (Switzerland)

^j PAPA GIOVANNI XXIII HOSPITAL   (Italy)

more..

Author keywords

[No Author keywords available]

Indexed keywords

HEMOGLOBIN; RUXOLITINIB; PYRAZOLE DERIVATIVE;

ABDOMINAL PAIN; ACUTE KIDNEY FAILURE; ALLELE; ANEMIA; AORTA THROMBOSIS; ARTHRALGIA; ARTICLE; ASTHENIA; BACKACHE; BASAL CELL CARCINOMA; BLEEDING; BODY WEIGHT DISORDER; BRONCHITIS; COMPASSIONATE USE; CONSTIPATION; CONTROLLED STUDY; COUGHING; CROSSOVER PROCEDURE; CYSTITIS; DECREASED APPETITE; DEEP VEIN THROMBOSIS; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DYSPNEA; EPISTAXIS; FATIGUE; FEVER; GASTROENTERITIS; GENERAL CONDITION DETERIORATION; HEADACHE; HEART FAILURE; HEMATOMA; HERPES ZOSTER; HUMAN; HYPERTENSION; INSOMNIA; LEUKEMIA; LIMB PAIN; LONG TERM CARE; LYMPHATIC PARAMETERS; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE SPASM; MYELOFIBROSIS; NAUSEA; NIGHT SWEAT; NON MELANOMA SKIN CANCER; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PERIPHERAL EDEMA; PHASE 3 CLINICAL TRIAL; PNEUMONIA; PORTAL VEIN THROMBOSIS; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SEPSIS; SEPTIC SHOCK; SKIN CARCINOMA; SPLEEN VOLUME; THROMBOCYTOPENIA; TREATMENT RESPONSE; TUBERCULOSIS; URINARY TRACT INFECTION; VEIN THROMBOSIS; VOMITING; WEIGHT GAIN; ADULT; AGED; CLINICAL TRIAL; DISEASE COURSE; DRUG EFFECTS; FEMALE; FOLLOW UP; MALE; MIDDLE AGED; MORTALITY; ORGAN SIZE; PRIMARY MYELOFIBROSIS; SPLEEN; SURVIVAL RATE; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; CROSS-OVER STUDIES; DISEASE PROGRESSION; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; ORGAN SIZE; PRIMARY MYELOFIBROSIS; PYRAZOLES; SPLEEN; SURVIVAL RATE;

EID: 84975123175     PISSN: 08876924     EISSN: 14765551     Source Type: Journal    
DOI: 10.1038/leu.2016.148     Document Type: Article

References (34)

1. Vannucchi AM. Management of myelofibrosis. Hematol Am Soc Hematol Educ Program 2011; 2011: 222-230
2. Vainchenker W, Delhommeau F, Constantinescu SN, Bernard OA. New mutations and pathogenesis of myeloproliferative neoplasms. Blood 2011; 188: 1723-1735
3. Abdel-Wahab O, Pardanani A, Rampal R, Lasho TL, Levine RL, Tefferi A. DNMT3A mutational analysis in primary myelofibrosis, chronic myelomonocytic leukemia and advanced phases of myeloproliferative neoplasms. Leukemia 2011; 25: 1219-1220
4. Mesa RA, Schwager S, Radia D, Cheville A, Hussein K, Niblack J, et al. The Myelofibrosis Symptom Assessment Form (MFSAF): an evidence-based brief inventory to measure quality of life and symptomatic response to treatment in myelofibrosis. Leuk Res 2009; 33: 1199-1203
5. Cervantes F, Dupriez B, Pereira A, PassamontiF, Reilly JT, Morra E, et al. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009; 113: 2895-2901
6. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Pereira, et al. A dynamic prognostic model to predict survival in primary myelofibrosis: a study by the IWG-MRT (International Working Group for Myeloproliferative Neoplasms Research and Treatment). Blood 2010; 115: 1703-1708
7. Quintás-Cardama A, Vaddi K, Liu P, Manshouri T, Li J, Scherle PA, et al. Preclinical characterization of the selective JAK1/2 inhibitor INCB018424: therapeutic implications for the treatment of myeloproliferative neoplasms. Blood 2010; 115: 3109-3117
8. Harrison C, Kiladjian JJ, Al-Ali HK, Gisslinger H, Waltzman R, Stalbovskaya V, et al. JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis. N Engl J Med 2012; 366: 787-798
9. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 2012; 366: 799-807
10. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. Efficacy, safety and survival with ruxolitinib in patients with myelofibrosis: results of a median 2-year follow-up of COMFORT-I. Haematologica 2013; 98: 1865-1871
11. Passamonti F, Maffioli M, Cervantes F, Vannucchi AM, Morra E, Barbui T, et al. Impact of ruxolitinib on the natural history of primary myelofibrosis: a comparison of the DIPSS and the COMFORT-2 cohorts. Blood 2014; 123: 1833-1835
12. Verstovsek S, Kantarjian HM, Estrov Z, Cortes JE, Thomas DA, Kadia T, et al. Long-Term outcomes of 107 patients with myelofibrosis receiving JAK1/JAK2 inhibitor ruxolitinib: survival advantage in comparison to matched historical controls. Blood 2012; 120: 1202-1209
13. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. Haematologica 2015; 100: 479-488
14. Cervantes F, Vannucchi AM, Kiladjian JJ, Al-Ali HK, Sirulnik A, Stalbovskaya V, et al. Three-year efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for myelofibrosis. Blood 2013; 122: 4047-4053
15. Robins JM, Tsiatis AA. Correcting for noncompliance in randomized trials using rank preserving structural failure time models. Commun Stat Theory Methods 1991; 20: 2609-2631
16. Korhonen P, Zuber E, Branson M, Hollaender N, Yateman N, Katiskalahti T, et al. Correcting overall survival for the impact of crossover via a rank-preserving structural failure time (RPSFT) model in the RECORD-1 trial of everolimus in metastatic renal-cell carcinoma. J Biopharm Stat 2012; 22: 1258-1271
17. Latimer NR, Abrams KR, Lambert PC, Crowther MJ, Wailoo AJ, Morden JP, et al. Adjusting for survival time estimates to account for treatment switching in randomized controlled trials-An economic evaluation context: methods, limitations, and recommendations. Med Decis Making 2014; 34: 387-402
18. Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008; 22: 14-22
19. Levine RL, Belisle C, Wadleigh M, Zahrieh D, Lee S, Chagnon P, et al. X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoiesis. Blood 2006; 107: 4139-4141
20. Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A. European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005; 90: 1128-1132
21. Cervantes F, Kiladjian JJ, Niederwieser D, Sirulnik A, Stalbovskaya V, McQuitty M, et al. Long-Term efficacy, safety, and survival findings from COMFORT-II, a phase 3 study comparing ruxolitinib with best available therapy for the treatment of myelofibrosis. Blood 2012; 120: abstract 801
22. Deininger M, Radich J, Burn TC, Huber R, Paranagama D, Verstovsek S. The effect of long-Term ruxolitinib treatment on JAK2p.V617F allele burden in patients with myelofibrosis. Blood 2015; 126: 1551-1554
23. Wilkins BS, Radia D, Woodley C, Farhi SE, Keohane C, Harrison CN. Resolution of bone marrow fibrosis in a patient receiving JAK1/JAK2 inhibitor treatment with ruxolitinib. Haematologica 2013; 98: 1872-1876
24. Kvasnicka HM, Thiele J, Bueso-Ramos CE, Sun W, Cortes J, Kantarjian HM, et al. Changes in bone marrow morphology in patients with myelofibrosis treated for up to 5 years with either ruxolitinib or best available therapy. Haematologica 2014; 99(Suppl 1): 127 (abstract P405)
25. Vannucchi AM, Kantarjian HM, Kiladjian JJ, Gotlib J, Cervantes F, Mesa RA, et al. A pooled analysis of overall survival in COMFORT-I and COMFORT-II, 2 randomized phase 3 trials of ruxolitinib for the treatment of myelofibrosis. Haematologica 2015; 100: 1139-1145
26. Al-Ali HK, Stalbovskaya V, Gopalakrishna P, Perez Ronco J, Foltz LM. Ruxolitinib overcomes the adverse prognostic effect of anemia in patients with myelofibrosis. Blood 2014; 124: abstract 4583
27. Polverelli N, Breccia M, Benevolo G, Martino B, Tieghi A, Latagliata R, et al. Risk factors for infections in myelofibrosis: role of disease status and treatment. A study on 507 patients. Blood 2015; 126: abstract 1606
28. Hultcrantz M, Lund SH, Andersson TM, Björkholm M, Kristinsson S. Myeloproliferative neoplasms and infections; a population-based study on 9, 665 patients with myeloproliferative neoplasms diagnosed in Sweden 1987-2009. Haematologica 2015; 100(Suppl 1): 260 (abstract P666)
29. Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013; 27: 1874-1881
30. Hasselbalch HC. Perspectives on the impact of JAK-inhibitor therapy upon inflammation-mediated comorbidities in myelofibrosis and related neoplasms. Expert Rev Hematol 2014; 7: 203-216
31. Kvasnicka HM, Thiele J, Bueso-Ramos CE, Sun W, Cortes J, Kantarjian HM, et al. Effects of five years of ruxolitinib therapy on bone marrow morphology in patients with myelofibrosis and comparison with best available therapy. Blood 2013; 122: abstract 4055
32. Passamonti F, Cervantes F, Vannucchi AM, Morra E, Rumi E, Cazzola M, et al. Dynamic International Prognostic Scoring System (DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood 2010; 116: 2857-2858
33. Verstovsek S, Mesa RA, Gotlib J, Levy RS, Gupta V, DiPersio JF, et al. The clinical benefit of ruxolitinib across patient subgroups: analysis of a placebo-controlled, phase III study in patients with myelofibrosis. Br J Haematol 2013; 161: 508-516
34. Barosi G, Tefferi A, Besses C, Birgegard G, Cervantes F, Finazzi G, et al. Clinical end points for drug treatment trials in BCR-ABL1-negative classic myeloproliferative neoplasms: consensus statements from European LeukemiaNET (ELN) and International Working Group-Myeloproliferative Neoplasms Research and Treatment (IWG-MRT). Leukemia 2015; 29: 20-26